4-Hydroxytamoxifen, an active metabolite of tamoxifen, does not alter the radiation sensitivity of MCF-7 breast carcinoma cells irradiatedin vitro

This publication has 28 references indexed in Scilit:

• Effects of Tamoxifen on the Radiosensitivity of Hormonally Responsive and Unresponsive Breast Carcinoma Cells
  Radiation Oncology Investigations, 1993
• The effect of adjuvant tamoxifen: The latest results from the Cancer Research Campaign adjuvant breast trial
  European Journal Of Cancer, 1992
• Proliferation indices of invasive breast carcinomas after in vivo 5-bromo-2′-deoxyuridine labelling: A flow cytometric study of 75 tumours
  British Journal of Surgery, 1992
• Long-Term Effects of Adjuvant Tamoxifen and/or Radiotherapy: The South Sweden Breast Cancer Trial
  Acta Oncologica, 1992
• Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
  The Lancet, 1992
• Proliferative inhibition of human breast carcinoma cells by high concentration estradiol does not alter radiosensitivity
  Breast Cancer Research and Treatment, 1991
• Modulation in the radiosensitivity of MCF-7 human breast carcinoma cells by 17B-estradiol and tamoxifen
  The British Journal of Radiology, 1989
• A Randomized Clinical Trial Evaluating Tamoxifen in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor–Positive Tumors
  New England Journal of Medicine, 1989
• Contrasting ability of antiestrogens to inhibit MCF-7 growth stimulated by estradiol or epidermal growth factor
  European Journal of Cancer and Clinical Oncology, 1989
• Radiation-induced Potentially Lethal Damage: DNA Lesions Susceptible to Fixation
  International Journal of Radiation Biology, 1988